Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Aalborg Universityhospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Aalborg Universityhospital
Information provided by:
Aalborg Universityhospital
ClinicalTrials.gov Identifier:
NCT00451984
First received: March 23, 2007
Last updated: October 31, 2007
Last verified: October 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130302094045im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Hepatitis A Hepatitis B |
Biological: Twinrix Biological: interleukin-2 |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
Resource links provided by NLM:
Further study details as provided by Aalborg Universityhospital:
![](https://webarchive.library.unt.edu/web/20130302094045im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults with stable antiretroviral therapy and negative for hepatitis A or B
Exclusion Criteria:
- Prior hepatitis A or B
![](https://webarchive.library.unt.edu/web/20130302094045im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00451984
Contacts
Contact: Henrik Nielsen, MD, DMSci | +45-99326525 | henrik.nielsen@rn.dk |
Locations
Denmark | |
Department of Infectious Diseases, Aalborg Hospital | Recruiting |
Aalborg, Denmark, DK9000 | |
Principal Investigator: Raquel M Iguacel, MD | |
Sub-Investigator: Henrik Nielsen, MD, DMSci | |
Department of Infectious Diseases, Skejby Hospital | Not yet recruiting |
Aarhus, Denmark, DK8200 | |
Contact: Alex Laursen, MD, DMSci +45-89495566 | |
Principal Investigator: Ole Søgaard, MD |
Sponsors and Collaborators
Aalborg Universityhospital
Investigators
Study Chair: | Henrik Nielsen, MD, DMSci | Aalborg Hospital, DK-9000 Aalborg, Denmark |
![](https://webarchive.library.unt.edu/web/20130302094045im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
ClinicalTrials.gov Identifier: | NCT00451984 History of Changes |
Other Study ID Numbers: | VN2005/32 |
Study First Received: | March 23, 2007 |
Last Updated: | October 31, 2007 |
Health Authority: | Denmark: Danish Medicines Agency |
Keywords provided by Aalborg Universityhospital:
interleukin-2 vaccination treatment experienced |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Hepatitis Hepatitis A Hepatitis B Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Liver Diseases |
Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections Hepadnaviridae Infections DNA Virus Infections Interleukin-2 Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on February 28, 2013